Deep Track Capital, LP Increases Stake in Definium Therapeutics (MNMD) to 3.01%

On May 15, 2026, Deep Track Capital, LP, filed a Schedule 13G/A regarding its holdings in Definium Therapeutics, Inc. (ticker: MNMD). The filing indicates that as of the event date on March 31, 2026, the reporting persons—including Deep Track Biotechnology Master Fund, Ltd. and David Kroin—collectively hold 3,000,000 common shares. This position represents a 3.01% ownership stake in the company, based on approximately 99.7 million shares outstanding. This filing serves as an amendment (Amendment No. 4) and reflects an increase in holdings compared to the previously reported 0.0% ownership. The reporting persons have shared voting and dispositive power over all 3,000,000 shares. The filing was made under Rule 13d-1(c), certifying that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Deep Track Capital, LP operates as the investment adviser, with David Kroin serving as a control person.